Specialties – Page 184

Minimally Invasive Surgery versus Medical Management for Supratentorial Intracerebral Hemorrhage: Insights from the MIND Trial

By MedXY 09/26/2025

The MIND trial compared minimally invasive surgery using the Artemis device to standard medical management for supratentorial intracerebral hemorrhage, finding no significant improvement in 180-day functional outcomes or 30-day mortality with surgery.

General Surgery Neurology news Specialties

Minimally Invasive Surgery vs Medical Management in Supratentorial Intracerebral Hemorrhage: Insights from the MIND Randomized Trial

By MedXY 09/26/2025

The MIND trial found no significant functional benefit or mortality reduction with minimally invasive surgery compared to medical management alone in supratentorial intracerebral hemorrhage patients at 180 days.

Clinical Updates Diabetes & Endocrinology news

What’s New in the ADA 2024 Standards of Care: Practical Guidance on Weight‑Lowering Drugs, Cardiorenal Protection, and Technology for Diabetes

By MedXY 09/26/2025

The ADA 2024 Standards update care pathways for diabetes with stronger guidance on obesity pharmacotherapy (GLP‑1/GIP agents), earlier use of SGLT2/GLP‑1 for cardiorenal benefit, and expanded technology recommendations.

Neurology news

Sustained Symptom Control over Five Years: Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease

By MedXY 09/26/2025

Five-year follow-up from the INTREPID trial confirms that subthalamic nucleus deep brain stimulation significantly improves motor symptoms, reduces dyskinesia, lowers medication needs, and enhances daily living activities in moderate to advanced Parkinson disease patients, with an acceptable safety profile.

Clinical Updates Neurology news

Long-Term Safety and Effectiveness of Personalized Adaptive Deep Brain Stimulation in Parkinson’s Disease

By MedXY 09/26/2025

This international trial demonstrates that personalized adaptive deep brain stimulation (aDBS) is a safe, effective, and well-tolerated long-term therapy for Parkinson's disease patients previously stable on continuous DBS.

Family Medicine & Nutrition Oncology Specialties

Vitamin B12 Supplementation Halves Risk of Chemotherapy-Induced Hand-Foot Syndrome in Early Breast Cancer Patients

By MedXY 09/25/2025

A phase 3 trial finds high-dose oral vitamin B12 significantly reduces moderate-to-severe hand-foot syndrome in women receiving capecitabine chemotherapy, without increasing toxicity, offering a safe and convenient preventive option.

news Psychiatry

Cytisinicline Enhances Smoking Cessation in COPD Patients: Post Hoc Insights from the ORCA-2 and ORCA-3 Trials

By MedXY 09/25/2025

Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.

Clinical Updates Family Medicine & Nutrition news Specialties

Do Oily Fish Intake Increase Pancreatic Cancer Risk?

By MedXY 09/25/2025

This Mendelian randomization study reveals a surprising association between higher oily fish consumption and increased pancreatic cancer risk, highlighting new directions for dietary guidance and pancreatic disease prevention.

Clinical Updates news OB/GYN & Women's Health Oncology

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

By MedXY 09/25/2025

The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Promising Links Between Diabetes Medications and Alzheimer’s Disease Risk Reduction

By MedXY 09/25/2025

Recent real-world data suggest GLP-1 receptor agonists and SGLT2 inhibitors may lower Alzheimer’s disease risk more effectively than DPP-4 inhibitors, highlighting the need for randomized trials to confirm potential neuroprotective benefits.

General Surgery Neurology Specialties

Hyperbaric Oxygen Therapy Enhances Recovery After Intracranial Aneurysm Surgery

By MedXY 09/25/2025

A meta-analysis of 11 RCTs involving over 2000 patients shows hyperbaric oxygen therapy significantly improves neurologic function, independence, and quality of life post-intracranial aneurysm surgery.

Clinical Updates Gastroenterology news

Decoding the Role of Reflux Secondary Bile Acids in Barrett’s Esophagus: Microbiome and Transcriptome Insights

By MedXY 09/25/2025

This study reveals that elevated reflux secondary bile acids in Barrett's esophagus influence the esophageal microbiome and gene expression, highlighting potential mechanisms underpinning progression to esophageal adenocarcinoma.

Clinical Updates news Pathology & Lab Medicine Public Health Specialties

Is Single-Test Tuberculosis Screening Adequate Before Initiating Biologic Therapy?

By MedXY 09/25/2025

A 20-year cohort study indicates that using QuantiFERON-TB Gold alone for TB screening before biologic therapy effectively reduces TB infection diagnoses and preventive treatments without increasing active TB risk, questioning the need for dual testing or routine retesting.

Allergy & Immunology Dermatology Specialties

Icotrokinra: A Promising Oral IL-23 Inhibitor Outperforms JAK Inhibitor in Psoriasis Phase 3 Trials

By MedXY 09/25/2025

In two phase 3 trials, oral IL-23 receptor inhibitor icotrokinra demonstrated superior efficacy and safety compared to the JAK inhibitor deucravacitinib in moderate-to-severe plaque psoriasis, marking a potential advancement in oral psoriasis therapies.

Clinical Updates news Oncology

Reevaluating the Role of Adjuvant Immunotherapy After Neoadjuvant Chemoimmunotherapy in Resectable Stage III NSCLC: Results from a Two-Center Real-World Study

By MedXY 09/25/2025

This study suggests adjuvant immunotherapy may not enhance survival after neoadjuvant chemoimmunotherapy and surgery in stage III NSCLC, with three cycles of neoadjuvant immunotherapy appearing optimal.

news Oncology Specialties

Pembrolizumab Plus Platinum-Based Chemotherapy Shows Promise in Advanced Penile Cancer: Results from the HERCULES Trial

By MedXY 09/25/2025

The HERCULES trial demonstrates that pembrolizumab combined with platinum-based chemotherapy yields a 39.4% response rate and manageable safety in advanced penile squamous cell carcinoma, offering new hope for this underserved cancer population.

Clinical Updates news Oncology Specialties

Clarifying the Role of Repeat PSA Testing: Insights from the PLCO Cancer Screening Trial

By MedXY 09/25/2025

Annual PSA testing exhibits significant intra-individual variability; many elevated PSA levels normalize upon retesting, supporting guidelines recommending repeat testing before biopsy, with exceptions for patients with persistently elevated PSA.

Clinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY 09/25/2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.

Clinical Updates news Public Health

Violence Against Women and Girls in Conflict Zones: Progress, Challenges, and Future Priorities

By MedXY 09/25/2025

Conflict-related gender-based violence against women and girls is rising globally, exacerbated by inadequate funding and systemic neglect. Emerging evidence supports community-led prevention and survivor-centered responses, emphasizing women's leadership as vital in conflict and humanitarian settings.

Clinical Updates General Surgery news Transplantation

Combined Liver–Kidney Transplantation: Four Decades of Transformative Impact and Future Horizons

By MedXY 09/25/2025

Since the landmark combined liver–kidney transplant in 1984, advances in surgical techniques, immunosuppression, and donor allocation have revolutionized care for patients with dual organ failure. Emerging innovations, including gene-edited xenotransplantation, promise further breakthroughs.